Showing 71 - 80 of 7,105
The Canadian Common Drug Review (CDR) was established in 2003 to provide a single process for making formulary recommendations to most Canadian publicly funded drug plans. This paper considers the most common challenges faced by the CDR: (a) determining the effectiveness of a drug (particularly...
Persistent link: https://www.econbiz.de/10005449239
Persistent link: https://www.econbiz.de/10005449299
Since 1999, the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Programme has been charged with producing guidance for the NHS in England and Wales on the appropriate use of new and existing healthcare programmes. Guidance is based on an assessment of a number...
Persistent link: https://www.econbiz.de/10005449300
This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how...
Persistent link: https://www.econbiz.de/10005449318
Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly...
Persistent link: https://www.econbiz.de/10005404768
The National Institute for Health and Clinical Excellence (NICE) has been using a cost-effectiveness threshold range between Lstg 20_000 and Lstg 30_000 for over 7 years. What the cost-effectiveness threshold represents, what the appropriate level is for NICE to use, and what the other factors...
Persistent link: https://www.econbiz.de/10005404787
Indirect and mixed treatment comparison (MTC) approaches to synthesis are logical extensions of more established meta-analysis methods. They have great potential for estimating the comparative effectiveness of multiple treatments using an evidence base of trials that individually do not compare...
Persistent link: https://www.econbiz.de/10005404800
DOI: 10.2165/0019053-200826110-00002
Persistent link: https://www.econbiz.de/10005404814
Cost-effectiveness analysis has been advocated in the health economics methods literature and adopted in a growing number of jurisdictions as an evidence base for decision makers charged with maximising health gains from available resources. This paper critically appraises the information...
Persistent link: https://www.econbiz.de/10005404817
arthritis), whereas WTP values for insulin and post-operative emesis therapy were very divergent. No single methodological …
Persistent link: https://www.econbiz.de/10005404845